Climb Bio (CLYM) to Release Quarterly Earnings on Tuesday

Climb Bio (NASDAQ:CLYM) is expected to announce its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Climb Bio to post earnings of ($0.17) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 9:30 AM ET.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.06. On average, analysts expect Climb Bio to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Climb Bio Trading Down 4.0%

Shares of Climb Bio stock traded down $0.08 during mid-day trading on Tuesday, hitting $1.92. 68,486 shares of the stock were exchanged, compared to its average volume of 429,749. Climb Bio has a twelve month low of $1.05 and a twelve month high of $4.34. The stock has a market capitalization of $130.10 million, a price-to-earnings ratio of -2.74 and a beta of -0.06. The company has a 50-day simple moving average of $2.12 and a 200 day simple moving average of $1.65.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CLYM. Shay Capital LLC raised its holdings in Climb Bio by 107.5% in the second quarter. Shay Capital LLC now owns 415,000 shares of the company’s stock valued at $515,000 after buying an additional 215,000 shares during the period. Jane Street Group LLC purchased a new stake in shares of Climb Bio during the second quarter valued at approximately $184,000. Goldman Sachs Group Inc. acquired a new stake in shares of Climb Bio during the first quarter worth approximately $147,000. Marshall Wace LLP acquired a new stake in shares of Climb Bio during the second quarter worth approximately $46,000. Finally, Qube Research & Technologies Ltd acquired a new stake in shares of Climb Bio during the second quarter worth approximately $43,000. Hedge funds and other institutional investors own 69.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Climb Bio from a “sell” rating to a “hold” rating in a research note on Monday, October 6th. William Blair assumed coverage on shares of Climb Bio in a research note on Thursday, October 16th. They set an “outperform” rating on the stock. HC Wainwright initiated coverage on shares of Climb Bio in a research note on Monday, October 13th. They set a “buy” rating and a $9.00 price target on the stock. BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of Climb Bio in a report on Thursday, October 16th. Finally, Baird R W upgraded shares of Climb Bio to a “strong-buy” rating in a report on Friday, August 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $9.20.

About Climb Bio

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.